Solid Biosciences (SLDB) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SLDB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLDB, but not buy additional shares or sell existing shares.
View SLDB analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued twelve-month price objectives for Solid Biosciences' shares. Their SLDB share price forecasts range from $15.00 to $90.00. On average, they predict the company's stock price to reach $52.50 in the next twelve months. This suggests a possible upside of 749.5% from the stock's current price.
View analysts price targets for SLDB or view top-rated stocks among Wall Street analysts.

Solid Biosciences' stock was trading at $5.38 at the beginning of the year. Since then, SLDB shares have increased by 14.9% and is now trading at $6.18.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SLDB earnings forecast.

Solid Biosciences Inc. (NASDAQ:SLDB) issued its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($2.70) by $2.02.

Shares of Solid Biosciences reverse split on Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).

(SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

Solid Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (3.30%), Finepoint Capital LP (2.50%), Great Point Partners LLC (1.07%), BlackRock Inc. (0.71%), Geode Capital Management LLC (0.21%) and Renaissance Technologies LLC (0.20%). Insiders that own company stock include Carl Ashley Morris, Ilan Ganot, Jennifer Lynn Ziolkowski, Joel Solomon Zev Schneider, Perceptive Advisors Llc and Ra Capital Management, LP.
View institutional ownership trends.

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SLDB stock can currently be purchased for approximately $6.18.

Solid Biosciences (NASDAQ:SLDB) has a market capitalization of $121.13 million and generates $8.09 million in revenue each year. The company earns $-85,980,000.00 in net income (profit) each year or ($8.2284) on an earnings per share basis.

The company employs 104 workers across the globe.

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.solidbio.com. The company can be reached via phone at (617) 337-4680.